AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24.

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

The personal luxury goods market looks set to face its first slowdown since the Global Financial Crisis, excluding the Covid ...

Although some products like Imfinzi/Imjudo and Soliris underperformed, overall, the company’s performance was bolstered by significant gains in other segments, such as Symbicort and Ultomiris.

The brand spent an estimated $18.1 million on national TV advertising ... The bottom half of the list featured Reckitt ...

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

AstraZeneca is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The United Kingdom-based global biopharmaceutical company said it ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...